Diabetes Drugs That Quietly Lower Blood Pressure: Inside the GLP-1 Mechanism

Glucagon-like peptide-1 receptor agonists have become the most talked-about drugs in medicine, celebrated first for transforming type 2 diabetes care and more recently for their striking effects on body weight. But a new synthesis published in Pharmacology Research & Perspectives argues that one of their most consequential actions has been hiding in plain sight: a small but remarkably consistent lowering of systolic blood pressure. The review, which integrates molecular, vascular, renal and clinical evidence, concludes that these drugs act on blood pressure through a convergence of mechanisms rather than a single pathway, and that the benefit appears confined to people whose blood pressure is elevated in the first place. That nuance matters, because hypertension is one of the most powerful drivers of the heart attacks, strokes and cardiovascular deaths that GLP-1 receptor agonists are increasingly known to prevent.

To understand how a diabetes drug touches the vascular system, it helps to start with the hormone it mimics. GLP-1 is an incretin hormone released by enteroendocrine L-cells in the distal ileum and colon after a meal. When glucose or other nutrients arrive in the gut, these cells close ATP-dependent potassium channels, depolarize the membrane, open L-type calcium channels and secrete GLP-1 into the bloodstream. The hormone then amplifies insulin secretion from pancreatic beta cells by two- to three-fold compared with intravenous glucose, a phenomenon known as the incretin effect. It also delays gastric emptying and suppresses glucagon release. In type 2 diabetes, this incretin effect is blunted, partly through impaired GLP-1 function and reduced receptor expression, which is precisely why pharmacological boosting of the pathway has proven so effective.

Native GLP-1, however, is a fleeting molecule. The enzyme dipeptidyl peptidase-4 cleaves it within minutes, leaving a circulating half-life of roughly ninety seconds, so a substantial fraction of the hormone is inactivated before it ever reaches its targets. Therapeutic agonists were engineered to escape this fate. Exenatide, derived from a peptide found in the saliva of the Gila monster, survives for about 2.4 hours and was approved in 2005 for twice-daily injection. Liraglutide carries a fatty-acid side chain that binds reversibly to serum albumin, extending its half-life to 13 to 15 hours after subcutaneous injection. Semaglutide, dulaglutide and albiglutide push persistence further still, with half-lives long enough to permit once-weekly dosing. Tirzepatide adds a second layer of sophistication by engaging the receptor for the other incretin hormone, GIP, as well as GLP-1.

All of these molecules converge on a single target: the GLP-1 receptor, a class B G protein-coupled receptor of 463 amino acids found in the pancreas, gastrointestinal tract, lungs, kidneys, central nervous system and, in mice, monkeys and humans, the heart. When activated, the receptor can couple to the Gs protein to raise cyclic AMP, to Gq/11 to elevate intracellular calcium, and to beta-arrestin to trigger ERK1/2 signaling. Crucially, different ligands bias the receptor toward different downstream cascades, a property known as biased agonism. The review highlights this as one plausible explanation for why structurally distinct agonists do not lower blood pressure to the same degree: they are not simply switching the receptor on, they are steering it toward different intracellular programs.

The vascular story begins in the endothelium. In human umbilical vein endothelial cells exposed to GLP-1, receptor activation recruits the phosphatidylinositol 3-kinase/Akt pathway, which phosphorylates and activates endothelial nitric oxide synthase, raising the bioavailability of nitric oxide, the principal relaxing factor of the vessel wall. A parallel protein kinase A-dependent route to nitric oxide production operates alongside it. Together these converging pathways relax vascular smooth muscle and reduce peripheral resistance. Downstream, activation of AMP-activated protein kinase and suppression of nuclear factor-kappa B signaling cut vascular oxidative stress, adhesion molecule expression and inflammatory cytokine release, linking the acute vasoactive effects of the receptor to the slower, anti-atherosclerotic remodeling of the vessel wall.

The heart and kidneys contribute their own mechanisms. In atrial cardiomyocytes, GLP-1 receptor activation couples to Epac2, triggering the secretion of atrial natriuretic peptide, which raises cyclic GMP and promotes both vasodilation and renal sodium excretion. Direct natriuresis has been documented in healthy, obese and type 2 diabetic individuals, offering a plausible route by which plasma volume, and with it blood pressure, is reduced. Evidence from mouse studies further suggests that exendin-4 can dampen angiotensin II signaling in the kidney, inhibiting the transforming growth factor beta1 and Smad3 pathway that drives fibrosis. Yet here the literature fractures: a clinical study of dulaglutide found no significant changes in plasma renin activity, serum aldosterone or related neurohormonal markers, leaving the role of the renin-angiotensin-aldosterone system unresolved and flagged by the review as a priority for further investigation.

The clinical data, drawn from cardiovascular outcome trials and pooled analyses, paint a picture of modest but persistent effect. Exenatide at 10 micrograms twice daily reduced systolic pressure by a least-squares mean of 2.8 mmHg across 2,171 patients, with the largest difference, 8.2 mmHg versus placebo, seen in people whose baseline systolic pressure exceeded 150 mmHg. Once-weekly exenatide lowered systolic pressure by 1.6 mmHg in the EXSCEL trial of nearly 14,752 patients. Dulaglutide at 1.5 milligrams produced a 2 to 3 mmHg reduction evident within four weeks and sustained through 26 weeks, accompanied by a fall in 24-hour pulse pressure. Semaglutide at 1.0 milligram weekly lowered systolic pressure by 2.6 mmHg in SUSTAIN-6, and oral semaglutide matched that figure at week 83 in PIONEER-6. Liraglutide managed 1.2 mmHg over 36 months in LEADER, while lixisenatide achieved only 0.8 mmHg in ELIXA. Diastolic pressure, by contrast, was largely untouched.

Two patterns emerge from those numbers. First, the effect is drug-specific: agents differ by more than threefold in the magnitude of systolic reduction they deliver, consistent with the biased agonism observed at the receptor. Second, the benefit is conditional. People with normal blood pressure at baseline showed no between-group differences in the trials, suggesting that GLP-1 receptor agonists act as regulators of an elevated system rather than as blanket antihypertensives. The review also draws a careful temporal distinction that has muddied the literature. Acutely, GLP-1 receptor stimulation of sinoatrial node pacemaker cells and brainstem autonomic neurons raises heart rate and can transiently nudge mean arterial pressure upward, particularly after dose escalation. Chronically, sustained therapy produces a net systolic reduction as weight loss, improved glycemic control and the vascular, renal and anti-inflammatory mechanisms accumulate and outweigh the initial pressor response. The two effects operate on different timescales and are not contradictory, but conflating them has fueled apparent inconsistencies across studies.

What the mechanisms cannot yet claim is firm human validation. Aside from the natriuresis and endothelial function data, most of the mechanistic evidence comes from animal models and in vitro systems, and blood pressure was rarely a pre-specified primary endpoint in the major cardiovascular outcome trials from which the clinical numbers are extracted. That makes it difficult to determine whether the observed 1 to 3 mmHg reductions translate into meaningful antihypertensive benefit independent of glycemic control or weight loss, and head-to-head comparisons between agents are lacking. The review calls for trials that place blood pressure at the center of the design, translational studies in human subjects to confirm the proposed nitric oxide, atrial natriuretic peptide and renin-angiotensin pathways, and stratified analyses to identify which patients, most plausibly those with elevated baseline pressure and coexisting type 2 diabetes, stand to gain the most.

Even within those limits, the synthesis carries a striking implication. A drug class developed to restore a gut hormone signal has turned out to engage nearly every major axis of cardiovascular regulation: endothelial nitric oxide signaling, natriuretic peptide release, renal sodium handling, vascular inflammation and atherosclerotic plaque biology. Liraglutide has been shown to suppress angiotensin II-induced inflammatory cascades in vessel walls, preventing the expression of ICAM-1, VCAM-1 and P-selectin on endothelial cells and restoring nitric oxide levels. Exenatide modulates matrix metalloproteinases in human coronary artery cells and shifts macrophages from a pro-inflammatory M1 state toward a reparative M2 phenotype, stabilizing atherosclerotic lesions. Semaglutide and liraglutide reduce plaque development in mice through AMPK activation and lowered proinflammatory cytokines. The blood pressure effect, small as it is, may be the visible surface of a much deeper vascular reprogramming, and understanding it fully could determine how these blockbuster drugs are positioned in the broader campaign against cardiovascular disease.

Subject of Research: Blood pressure regulation by glucagon-like peptide-1 receptor agonists and its cardiovascular mechanisms

Article Title: Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Article References: Alharbi, N. H. J. (2026). Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. Pharmacology Research & Perspectives, 14(5), Article e70329. https://doi.org/10.1002/prp2.70329

Image Credits: AI Generated

DOI: 10.1002/prp2.70329

Keywords: GLP-1 receptor agonists, blood pressure, hypertension, type 2 diabetes, nitric oxide, endothelial function, natriuresis, atrial natriuretic peptide, cardiovascular outcomes, semaglutide, liraglutide, incretin effect